Finally, we provided new pharmacological perspectives on the anti-inflammatory role of anticholinergic drugs in the treatment of COPD patients and described their ability to attenuate IL-17A-mediated TSLP production (Fig. 7). Here, IL17A is linked to chronic obstructive pulmonary disease.